Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

  • End date
    Jun 2, 2022
  • participants needed
  • sponsor
    Momenta Pharmaceuticals, Inc.
Updated on 15 August 2021
The Medical Research Network, LLC
Primary Contact
Momenta Investigational Site (0.0 mi away) Contact
+29 other location
immune globulin


The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.


The Part A of the study is currently not accepting healthy volunteers as the recruitment for the part A has completed.

Condition IDIOPATHIC THROMBOCYTOPENIC PURPURA, Autoimmune disease, Idiopathic Thrombocytopenic Purpura (ITP), Thrombocytopenic
Treatment Placebo, Intravenous immunoglobulin (IVIG), Biological: M254
Clinical Study IdentifierNCT03866577
SponsorMomenta Pharmaceuticals, Inc.
Last Modified on15 August 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note